Glenmark Pharmaceuticals Limited

Infobox Company
company_name = Glenmark Pharmaceuticals Ltd.
company_
image_size = 150px
vector_
company_type = Public
genre =
foundation = Mumbai, India (1977)
founder = Gracias Saldanha
location_city = Mumbai
location_country = India
location =
origins =
key_people = Gracias Saldanha
Mrs. B. E. Saldanha
Glenn Saldanha
area_served =
industry = Pharmaceuticals
products =
revenue =
operating_income =
net_income =
num_employees =
parent =
divisions =

owner =
company_slogan =
homepage =
dissolved =
footnotes =

Glenmark Pharmaceuticals Ltd is a research-driven, global, fully integrated pharmaceutical company headquartered at Mumbai, India. Its shares are listed on India’s two large stock exchanges, the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). It employs over 5000 people across its global operations across 80 countries.

Glenmark is a leader in India in the discovery of new molecules and is focused in the areas of inflammation [Asthma/COPD, etc.] and metabolic disorders [Diabetes, Obesity, etc.] . The Company is in the process of creating marketing front-ends for the launch of its proprietary products in the future. Glenmark’s speciality business alone is guided to generate US$ 306 Mn in Net Sales in FY 08. Glenmark’s first Asthma/COPD molecule, Oglemilast [GRC 3886] , was licensed out to Forest Laboratories and Teijin Pharma Limited for the North American and Japanese markets, respectively, in two landmark deals. Oglemilast is presently undergoing Phase II clinical trials in the US. GRC 6211, undergoing Phase II clinical trials in Europe, has been out-licensed to Eli Lilly & company.

Glenmark aspires to build end to end global capabilities similar to a Big Pharma Company. Glenmark’s branded generics business is spread over 85 countries currently organised around four business units, namely: India, Latin America, Semi-Regulated Markets and Europe. The Company also plans to build its presence in USA.

Vision

To emerge as a leading research-based, global, integrated pharmaceutical company.

"Research & Development'

Glenmark is among the few Indian pharmaceutical players targeting new drug discovery and biologics research. Glenmark has a strong pipeline of 11 research programs. The NCE pipeline comprises three molecules in Phase II and three in preclinical stages and the Company has further five NBEs in different stages of development.

Highlights:

 2004 - Signed a deal worth USD 190 Mn with Forest Laboratories for developing and marketing Oglemilast, Glenmark’s lead molecule for Asthma/ COPD, for the North American region

 2004 - Signed a deal worth USD 53 Mn with Teijin Pharma Ltd. for developing and marketing Oglemilast for the Japanese territory

 2005 - Signed a deal worth USD 240 Mn with Merck KGaA for developing and marketing GRC 8200, Glenmark’s lead molecule for treatment of type 2 diabetes for US, Europe and Japan

 2005 - Signed a deal with Napo Pharmaceuticals for developing and marketing Crofelemer, Napo’s lead candidate for treatment of diarrhoea, for over 140 countries

 2007 - Signed a deal with Dyax Corporation for performing funded biologics research for three of Glenmark’s targets in the areas of inflammation and oncology

 2007 - Signed a deal worth USD 350 Mn with Eli Lilly for developing and marketing GRC 6211, Glenmark’s lead molecule for treatment of pain conditions, for NA, Europe and Japan.

Accolades

• Emerging Company of the Year’, The Economic Times Awards for Corporate Excellence (October, 2007)

• Outlook Money-NDTV Profit Award 2006-07, in the category: Best Value Creator

• Seventh Pharma Excellence Award for the category “Excellence in Research & Development” (May 25, 2007)

• Chemtech Award (February 2007)

• The Pharma Excellence Award for ‘Excellence in R&D Innovation’ by Express Pharma (2006)

• Excellence in Industry instituted by Christian Chamber of Commerce and Industry (2006)

• The ‘Star Company in the SME Sector’ [SME - small & medium enterprises] by Business Standard (BS) Awards of the Year (2006)

• 4th Express Pharma Pulse Awards in the category of Overall Performance [Group C] (May 23, 2004)

Snapshots 2007

 Glenmark announced reorganization of its business into Specialty and Generics, to build scale and end to end capabilities in both businesses

 Glenmark signs a deal worth USD 350 Mn with Eli Lilly for developing and marketing GRC 6211, Glenmark’s lead molecule for treatment of pain conditions, for NA, Europe and Japan

 Glenmark was awarded its first 180 days of shared generic drug exclusivity for Trileptal by U.S. Food and Drug Administration

 Glenmark Pharmaceuticals South Africa signed a 10 year marketing and distribution rights agreement with MeyerZall Laboratories. With this, Glenmark has the widest topical dermatology baskets in South Africa

 USFDA approves additional Phase II study in COPD for Oglemilast (GRC 3886), Glenmark’s lead PDE4 inhibitor molecule (October 2007)

 Glenmark market capital crossed the Rs10000 crore (US$2.52bn) mark - brings Glenmark in the league of the top five pharmaceutical companies in India

 Glenmark received GMP approval from MHRA of UK for its state of the art semi-solids (ointments & creams) manufacturing plant at Baddi

 Glenmark Pharmaceuticals S.A., the Swiss subsidiary of GPL completed the purchase of two New Biological Entities (NBE’s), humanized monoclonal therapeutic antibodies, CHR-1103 and CHR-1201 from Chromos, Canada

 Glenmark concludes deal to acquire Medicamenta a.s., a pharmaceutical marketing and manufacturing company in the Czech Republic

 Dyax Corp. and Glenmark entered into a funded research agreement for the discovery of therapeutic antibodies

Glenmark recently re-organizedits business into Speciality and Generics. The reorganization was essential as both Glenmark’s Speciality and Generics business has grown rapidly, posing a challenge of managing two diverse businesses that had both attained a critical mass. The reorganization aims to promote sharper focus on generics and specialty as separate businesses with distinctive needs, skill-sets, objectives and growth imperatives and aligned management teams.

As a result of the reorganization, Glenmark has transferred its Generics and Active Pharmaceutical Ingredients (API) businesses to its subsidiary – Glenmark Generics Limited (GGL).

External links

* [http://www.glenmarkpharma.com/index.html Official site]
* [http://www.glenmark-generics.com/]

External links

* [http://www.glenmarkpharma.com/index.html Official site]